Instil Bio Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer. The company’s current work centers on tumor-infiltrating lymphocyte, or TIL, cell therapies designed to harness a patient’s own immune cells to attack solid tumors. Its pipeline also includes next-generation programs built around engineered TIL approaches and bispecific antibody candidates aimed at difficult-to-treat cancers. Instil Bio Inc. operates as a research-driven biotechnology business, combining cell therapy development, manufacturing expertise, and clinical-stage oncology programs to address areas of significant unmet medical need. Headquartered in Dallas, Texas, the company plays a specialized role in the oncology market through its focus on advanced immunotherapy platforms and novel therapeutic candidates.
Website3963 Maple Avenue
Dallas, TX, 75219
United States
Investors talking about TIL also mention
What share of all stock conversation is about TIL?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% 0 | 0% 0 |
Of the messages about TIL that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | — | 25.64% -46.84 | ||
| Bearish | — | — | — | 74.36% +46.84 |
Of the messages about TIL that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Analysts | — | — | — | 0.56% | ||
| Announcements | — | — | — | 91.62% | ||
| Controversies | — | — | — | 6.7% | ||
| Earnings | — | — | — | 0% | ||
| Macro | — | — | — | 0.56% | ||
| Technical Analysis | — | — | — | 0.56% |
Of the messages about TIL, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | — | — | 57.72% | ||
| Newcomers | — | — | — | 42.28% |